Whole-genome characterization and resistance-associated substitutions in a new HCV genotype 1 subtype
von Massow, Georg (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Garcia-Cehic, D. (Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas)
Gregori i Font, Josep (Roche Diagnostics S.L)
Rodríguez Frías, Francisco (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Macià, María Dolores (Institut d'Investigació Sanitària Illes Balears)
Escarda, Ana (Hospital Universitari Son Espases (Palma de Mallorca, Balears))
Esteban Mur, Juan Ignacio (Universitat Autònoma de Barcelona. Departament de Medicina)
Quer, Josep 1963- (Universitat Autònoma de Barcelona. Departament de Medicina)

Date:	2019
Abstract:	Hepatitis C virus (HCV) is a highly variable infectious agent, classified into 8 genotypes and 86 subtypes. Our laboratory has implemented an in-house developed high-resolution HCV subtyping method based on next-generation sequencing (NGS) for error-free classification of the virus using phylogenetic analysis and analysis of genetic distances in sequences from patient samples compared to reference sequences. During routine diagnostic, a sample from an Equatorial Guinea patient could not be classified into any of the existing subtypes. The whole genome was analyzed to confirm that the new isolate could be classified as a new HCV subtype. In addition, naturally occurring resistance-associated substitutions (RAS) were analyzed by NGS. Whole-genome analysis based on p-distances suggests that the sample belongs to a new HCV genotype 1 subtype. Several RAS in the NS3 (S122T, D168E and I170V) and NS5A protein (Q(1b)24K, R(1b)30Q and Y93L+Y93F) were found, which could limit the use of some inhibitors for treating this subtype. RAS studies of new subtypes are of great interest for tailoring treatment, as no data on treatment efficacy are reported. In our case, the patient has not yet been treated, and the RAS report will be used to design the most effective treatment.
Grants:	Ministerio de Economía y Competitividad IDI-20151125 Instituto de Salud Carlos III PI15/00856 Instituto de Salud Carlos III PI15/00829 Instituto de Salud Carlos III PI16/00337
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Subtype ; Direct-acting antivirals ; HCV ; Genotype 1
Published in:	Infection and drug resistance, Vol. 12 (2019) , p. 947-955, ISSN 1178-6973

DOI: 10.2147/IDR.S195441
PMID: 31118701

9 p, 1.3 MB

The record appears in these collections:
Articles > Research articles
Articles > Published articles